Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Pharmaceutical Industries Ltd.

https://www.tevapharm.com/

Latest From Teva Pharmaceutical Industries Ltd.

Trove Of Opioid Documents May Help Shape Public Health Policy

As sponsors and US FDA continue to face fallout, newly launched digital archive of industry documents from opioid litigation and settlements will be free public resource for those investigating activities that led to the opioid epidemic. It is modeled on the archive of tobacco industry documents, which has been the basis of about 1,000 scientific publications.

Advertising, Marketing & Sales Drug Safety

Aurobindo’s Latest Launches Include Truvada And Atripla Rivals

Aurobindo has announced the launch of generic versions of Truvada, Atripla, Minocin and Gleevec in the US. As its generics business grows in the US, Europe, Canada and the rest of the world markets, Aurobindo plans to establish itself in China. The Indian pharma company has also announced its plan to commission new facilities to serve the external market. 

Approvals Launches

Teva Identifies ‘Problem Pattern’ Of Complex CRLs Ahead Of GDUFA III

Forecasting up to a dozen complex generic launches by Teva in the US in 2021, executive vice-president for North America commercial Brendan O’Grady said Teva was continuing to push for changes to boost approval rates ahead of GDUFA III next year.

Generic Drugs Strategy

Teva: Biosimilars In The US Will Become Like Complex Generics

With a couple of major partnerships and a stable of internal projects, Teva expects to play a role in the “majority of meaningful US biosimilar launches in the next five-to-eight years,” executive vice-president for North America commercial Brendan O’Grady told Generics Bulletin in an exclusive interview.

Biosimilars Commercial
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Other Names / Subsidiaries
    • ABIC Marketing Limited
    • AbZ-Pharma
    • Auspex Pharmaceuticals, Inc. (Imphar AG)
    • Barr Pharmaceuticals
    • Bentley Pharmaceuticals
    • BioGeneriX AG
    • BioAssets Development Corporation
    • Cephalon, Inc. (Arana Therapeutics (Peptech and EvoGenix)
    • Ception Therapeutics
    • ChemGenex Pharmaceuticals Limited
    • CIMA Labs
    • Gemin X Pharmaceuticals
    • CT Arzneimittel GmbH
    • Gecko Health Innovations
    • IVAX Corporation
    • Labrys Biologics
    • Mepha
    • MicroDose Therapeutx Inc.
    • Neose Technologies, Inc.
    • NuPathe, Inc.
    • PLIVA HRVATSKA d.o.o.
    • ratiopharm Group
    • Sicor Biotech
    • Representaciones e Investigaciones Médicas, S.A. de C.V.
    • Taiyo Pharmaceutical Industry Co. Ltd.
    • Teva Branded Pharmaceutical Products, R&D Inc.
    • Teva Women's Health, Inc.
    • Actavis Generics
    • Anda, Inc.
    • Uteron Pharma S.P.R.L.
    • Teva Takeda Yakuhin Ltd.
    • Teva Takeda Pharma Ltd.
    • Teva Neuroscience, Inc.
    • Teva Pharmaceuticals USA, Inc.
    • Zeneus Pharma
UsernamePublicRestriction

Register